AstraZeneca's Bydureon pen now available in pharmacies

WILMINGTON, Del. — AAstraZeneca's once-weekly Bydureon (exenatide extended-release for injectable suspension) pen now is available in pharmacies across the United States, the company announced. The 2-mg prescription medicine is approved by the Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in adults who have Type 2 diabetes. 

 

“Bydureon is the first once-weekly treatment option for adults with Type 2 diabetes, and Bydureon pen now offers the same continuous release of exenatide in a pre-filled device,” said John Yee, M.D., VP, head of medical affairs, U.S. diabetes, AstraZeneca. “Bydureon has been shown to provide significant HbA1c reduction and, although not a weight-loss medicine, the additional benefit of weight loss.”

 

Bydureon is a pre-filled, single-use pen injector that contains the same formulation and dose as the Bydureon single-dose tray. The pen eliminates the need for the patient to transfer their medication between a vial and syringe during the process of self-injection. The Bydureon single-dose tray is still available for current and new patients, the company stated.